

EDITORIAL

(The editorials are written by the members of the Editorial Advisory Board or by guest writers. The editorials express the personal views of the writers.)

TREATMENT OF WARTS

The treatment of warts is at once simple as well as difficult. It is simple because the lesions can be easily destroyed by anything available at hand; at the same time it is difficult, because frequent recurrences are a common cause of frustration both to the patient and the treating dermatologist. The very fact that a variety of methods have been tried and are still being looked for, is a proof that there is no satisfactory method available so far.

Most reports mention that a significant proportion of warts disappear spontaneously within a period of 2 years¹⁻³, and therefore, one should play for time in the treatment of warts. The clinical indication of a spontaneous regression has been reported to be darkening of the wart or appearance of dark spots on its surface⁴. It is, however, also known that in the same patient, new lesions may continue to appear, when some of the old lesions are disappearing. Thus, as a practical approach, it may be difficult to convince a patient just to wait for the warts to disappear when it may not happen at all. Moreover, at a latter date a wart may become more difficult to treat, particularly if it extends under the nail plate or into the eye-lid margin. Therefore, the only reasonable indication for leaving the warts alone for spontaneous regression may be when the treatment seems likely to leave behind unwelcome sequelae, or when the patient refuses treatment.

The most logical method of treating warts seems to be the use of a specific anti-viral agent, but unfortunately no such agent is available to date. Trials with 5-fluorouracil (5-FU), a flourinated pyrimidine which can interfere with the synthesis of DNA showed cure rates of 67%⁵ and 46.5 to 53%⁶. Topical as well as intralesional 5-FU resulted in success in 75% cases⁷. In a controlled trial⁸ where the effect of 5-FU was compared in a double blind manner with a placebo, 5-FU was successful in 60% of the cases compared to 20% success with placebo. The method of using 5-FU consisted of applying a 5% ointment on the lesions and covering the lesions with a water-proof adhesive plaster for 24 hours. This treatment was repeated daily for 4 weeks. Although the results are encouraging, the method seems to be tedious and slow. Morison⁹ used 25% hydroxyurea in dimethyl sulphoxide (DMSO) and 40% idoxuridine (IDU) in DMSO for warts, but neither of these agents was effective. This failure being attributed to the effect of DMSO which leads to a very quick absorption of the compounds and thus allows very little time for the active ingredients to act on the wart tissue, IDU 40% was tried in a cream base with occlusion with very good results. Similar success was obtained with 20% IDU, but further lowering the concentration of IDU to 10%, made it much less effective. The duration of treatment in each case was 4 weeks. Bleomycin, a group of cytotoxic glycopeptide antibiotics derived

from *Streptomyces verticillus*, was used intravenously in 3 cases by Mishima and Matunaka¹⁰ with complete success. Bremner¹¹ used it intralesionally as a 0.1% solution in normal saline and found a cure rate of 63%; the lesions disappearing within 4 weeks. In most cases, a single injection was sufficient though in a few, a second injection was given after 4 weeks. The method is promising though availability of bleomycin could be a limitation. Podophyllum is the only antimitotic agent with an established role in the treatment of warts, but it is effective only in the genital warts. A 20-25% concentration in tincture benzoin is applied on the surface of the lesion after protecting the adjoining normal skin. After 2 hours, it can be washed off. The applications can be repeated once or twice a week if required². It is not effective in other types of warts because it is probably unable to penetrate the thickened stratum corneum.

In the absence of a specific and thoroughly evaluated anti-viral agent, the oldest and still the most widely used method for the treatment of warts consists of non-specific destruction of the infected tissue which automatically leads to elimination of the virus as well. Freezing of the tissue (Cryotherapy)^{12,13} with liquid air, liquid nitrogen or carbon dioxide snow can be used wherever facilities are available. The method consists of applying the agent on the wart for a period long enough to cause severe vasoconstriction and necrosis of the tissue. Freezing by itself leads to destruction of the tissue. Sanders and Stretcher⁸ stress the importance of formation of an 'ice ball' extending several millimeters beyond the wart. This leads to formation of a blister followed by crusting. Healing occurs in 7-10 days. Destruction of the tissue can also be achieved by local applications of strong acids or alkalis¹². The choice obviously

depends upon whatever is available and is strong enough to cause necrosis of the tissue, but carbolic acid (phenol) and trichloroacetic acid are the ones used most frequently. The agent has got to be pricked into the lesion by means of a hypodermic needle, because these acids as a rule, have only a limited capacity to penetrate the thickened stratum corneum. In case the lesions are big, surgical scooping of the main wart followed by cauterization of the base with phenol or trichloroacetic acid is necessary to destroy the left-over infected tissue¹⁴. The rate of success depends upon the thoroughness with which the infected tissue has been removed. It is necessary to examine the patient again within 2-3 weeks to detect recurrence of the treated lesions if any and also the appearance of new lesions which escaped detection earlier. For complete eradication, each lesion must be treated at the earliest, because the longer a lesion stays on the skin more likely it is to give rise to new lesions. This is particularly so when the lesions occur on the beard region where shaving facilitates cutting off of the wart tissue and its transplantation on new abraded areas. Warts can also be destroyed by electro-coagulation or electric cauterization in which case an electric electrode coagulates or chars the tissue. This procedure also requires the same precautions as cauterization with acids or alkalis. The amount of tissue destroyed with these procedures has got to be carefully regulated, because if the destruction is incomplete, the warts are likely to recur and if the destruction is more, the resultant scarring is likely to be unpleasant. For the same reason, surgical excision of the entire wart is not necessary, because it almost always leaves behind a scar which can be extremely painful when situated on the sole. Genital warts however, can sometimes be very big, particularly

during pregnancy. In such a situation surgical excision seems to be a preferred method of treatment.

Since infection with warts is limited to the epidermis only, the most logical non-specific destructive procedure would be use of agents which can cause dermo-epidermal separation. Such an agent will ensure total removal of the infected tissue without any risk of residual scarring. Cantharidin, a powerful acantholytic agent was first used by Epstein and Kligman¹⁵ and recently by Rosenberg et al¹⁶ as a 0.7% solution in a collodion base for local application on warts daily till a blister formed or the lesion disappeared. The lesions have been reported to heal within 10 days or so.

Limitation of the warts to the epidermis only and absence of an inflammatory reaction had led many workers to believe that the virus does not incite an immunological reaction. But the facts that (1) the infection is most frequent during childhood, it becomes less during adolescence and still less as the age advances, (2) the warts can regress spontaneously particularly after electro-coagulation of a few lesions¹⁷, (3) histopathological demonstration of round cell infiltrates at the base of some warts^{18,19} and (4) preponderance of warts in patients with immunosuppression²⁰⁻²³ did suggest that immunologic mechanisms may be playing a role. Antibodies to the warts virus were demonstrated by many workers²⁴⁻³⁰, but in general, no correlation could be found between the antibody levels and regression of the warts. Morison^{23,31} however, considered depression of the cell mediated immunity to be responsible for propagation of the warts. Levamisole, as a stimulant of cell mediated immunity, was tried by Helin and Bergh³² and also by Sutton³³ with apparent success in several cases. The treatment schedule used by Helin and Bergh consisted

of 50-150 mg levamisole on 3 consecutive days every 2 weeks for 6-18 weeks and that used by Sutton was 150 mg on 2 consecutive days per week for 7 months. Further trials on a larger number of cases preferably in a double blind manner are necessary to establish the usefulness of the agent because spontaneous regression of warts remains a possibility in all uncontrolled studies, and the record of levamisole as a stimulator of CMI is not uniformly good. Repeated small-pox vaccination was also tried in the past³⁴ probably on the basis of a similar mechanism but the practice has been given up because of serious side effects³.

Another interesting method to induce regression of the warts was tried by Greenberg et al³⁵. The patient was first sensitized by applying a 3 sq cm filter paper soaked with 0.05 ml of 30% DNCB in acetone on the patient's forearm for 24 hours. After 10 days the wart was challenged with 1-10 ug DNCB in acetone applied directly on the wart. In 4 out of 5 patients thus treated, the warts disappeared in 4-7 days. In 2 cases, even the unchallenged warts disappeared in 10-14 days. This method however, is risky and cannot be recommended for general adoption.

Other agents used for the treatment of warts include (1) soaking the wart bearing area (especially in the case of plantar warts) in 10% formaline¹² or 2% glutaraldehyde³⁶ for 15 minutes every day or applying 10% glutaraldehyde in ethanol or 5% glutaraldehyde in collodion on the lesions twice a day^{36,39}; (2) local applications of retinoic acid⁴⁰ on the warts once or twice a day, and (3) oral griseofulvin in 500 mg dose daily for 12 weeks⁴¹, but each of these methods needs further evaluation in properly controlled trials before they can be recommended for general adoption. The fact remains that the most ideal treatment must be

effective in almost all the patients, it should be simple and safe and should not leave behind residual scars.

Finally, it is also worthwhile to consider if a vaccine can be prepared to protect patients from warts. Theore-

tically, it seems possible to develop a vaccine which should enhance the cell mediated immunity against the virus, but for a disease which is neither lethal nor seriously disfiguring, necessity of a vaccine can be a debatable issue.

REFERENCES

— J. S. Pasricha, M.D., Ph D.
New Delhi

1. Rasmussen K A : On the spontaneous cure of plantar warts. *Acta Dermato-Venerol* 34 : 144, 1954.
2. Massing AM and Epstein WL : The natural history of warts *Arch Derm* 87 : 306, 1963.
3. Sanders BB and Stretcher GS : Warts. *Diagnosis and treatment. J Am Med Ass* 235 : 2859, 1976.
4. Brødersen I and Genner J : Histological and immunological observations on common warts in regression. *Acta Dermato-Venerol* 53 : 461, 1973.
5. Hursthouse MW : Treatment of warts with 5-fluorouracil. *Brit J Derm* 83 : 218, 1970.
6. Bunny M : The treatment of plantar warts with 5-fluorouracil *Brit J Derm* 89 : 96, 1973.
7. Jaross RW : *Skin Surgery* (Ed. Epstein) Charles C Thomas 1970, p 374.
8. Hursthouse MW : A controlled trial on the use of topical 5-fluorouracil on viral warts. *Brit J Derm* 92 : 93, 1975.
9. Morison WL : Antiviral treatment of warts. *Brit J Derm* 92 : 97, 1975.
10. Mishima Y and Matunaka M : Effect of bleomycin on benign and malignant cutaneous tumours. *Acta Dermato-Venerol* 52 : 211, 1972.
11. Bremner RM : Warts. Treatment with intralesional bleomycin. *Cutis* 18 : 264, 1976.
12. Burnett JW and Crutcher WA : Viral and rickettsial infections. In *Dermatology*. Editors Moschella SL Pillsbury DM and Hurlley HJ (Jr). WB Saunders Co. Philadelphia 1975.
13. Zacarian SA : Cryotherapy. In *Current Dermatologic Management*. Ed. Maddin S. CV Mosby Co. 1970
14. Pasricha JS : In *Treatment of Skin Diseases* Arnold Heinemann, New Delhi 1976.
15. Epstein WL and Kligman AM : Treatment of warts with cantharidin. *Arch Derm* 77 : 508, 1958.
16. Rosenberg EW, Amonette RA and Gardner JH : Cantharidin treatment of warts at home. *Arch Derm* 113 : 1134, 1977.
17. Reid TMS, Fraser NG and Kernohan IR : Generalized warts and immune deficiency. *Brit J Derm* 95 : 559, 1976.
18. Biberstein H : Immunisation therapy of warts. *Arch Derm and Syph* 50 : 12, 1944.
19. Tagami H, Ogino A, Takigawa M, Imamura S and Ofuji S : Regression of plane warts following spontaneous inflammation. *Erit J Derm* 90 : 147, 1974.
20. Spencer ES and Andersen HK : Clinically evident, non-terminal infections with herpes viruses and the wart virus in immunosuppressed renal allograft recipients. *Brit Med Journal* III : 251, 1970.
21. Koranda FC, Dehmel EM, Kahn G and Penn I : Cutaneous complications of immunosuppressed renal homograft recipients. *J Am Med* 229 : 419, 1974.
22. Perry TL and Harman L : Warts in diseases with immune defects *Cutis* 13 : 359, 1974.
23. Morison WL : Viral Warts, herpes simplex and herpes zoster in patients with secondary immune deficiencies and neoplasms. *Brit J Derm* 92 : 625, 1975.
24. Almeida JD and Goffe AP : Antibody to wart virus in human sera demonstrated by

TREATMENT OF WARTS

- electron microscopy and precipitin tests. *Lancet* II : 1205, 1965.
25. Ogilvie MM : Serological studies with human papova (wart) virus. *Journal of Hygiene* 68 : 479, 1970.
 26. Genner J : *Verrucae vulgaris* II. Demonstration of a complement fixation reaction. *Acta Dermato-Venercol* 51 : 365, 1971.
 27. Bunny MH, Hunter JAA, Ogilvie MM and Williams DA : The treatment of plantar warts in the home. A critical appraisal of a new preparation. *Practitioner* 207 : 197, 1971.
 28. Pyrhonen S and Penttinen K : Wart-virus antibodies and the prognosis of wart disease. *Lancet* II : 1330, 1972.
 29. Pass F and Maizel JV : Warts associated antigens. II. Human immunity to viral structural proteins. *J Invest Derm* 0 : 307, 1973.
 30. Matthews RS and Shirodaria PV : Study of regressing warts by immunofluorescence. *Lancet* I : 689, 1973.
 31. Morison WL : Cell mediated immune responses in patients with warts. *Brit J Derm* 93 : 553, 1975.
 32. Helin P and Bergh M : Levamisole for warts. *New Eng J Med* 291 : 1311, 1974.
 33. Sutton JD : Report on levamisole hydrochloride for warts. *Arch Derm* 113 : 521, 1977.
 34. McGee AR : Wart treatment by vaccination with small pox vaccine *Can Med Ass J* 99 : 119, 1968.
 35. Greenberg JH, Smith TL and Katz RM : *Verrucae vulgaris* rejection. *Arch Derm* 107 : 580, 1973.
 36. Allenby CF : The treatment of viral warts with glutaraldehyde. *The Brit J Clinical Practice* 31 : 12, 1977.
 37. London ID : Buffered glutaraldehyde solution for warts. *Arch Derm* 104 : 96, 1971.
 38. London ID : 24% glutaraldehyde solution for warts. *Arch Derm* 104 : 440, 1971.
 39. Bunny MH Nolan MW and Williams DA : An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. *Brit J Derm* 94 : 667 1976.
 40. Bersaques JD : Vitamin A acid in the topic treatment of warts. *Acta Dermato-Venercol (Suppl)* 74 : 169, 1975.
 41. Kapur TR and Singh OP : Griseofulvin therapy of viral warts. *Ind. J Derm Vener and Leprol* (In press).